Caplin Point Laboratories has announced strong financial performance for the fiscal year ended March 31, 2026. The company reported a total revenue of ₹2,303 crores and a Profit After Tax (PAT) of ₹650 crores, marking a 20.1% year-on-year increase. In recognition of this growth, the Board has declared an interim dividend of ₹4.00 per equity share (200%) for the financial year.
Annual Financial Performance
For the financial year ended March 31, 2026, Caplin Point Laboratories delivered a robust performance with total revenue reaching ₹2,303 crores, representing a 13.2% growth over the previous year. The company’s profitability also saw a significant surge, with PAT rising to ₹650 crores, a 20.1% increase compared to FY25. Basic EPS for the full year improved to ₹84.36 from ₹70.57 in the preceding year.
Strategic Dividends and Future Growth
The Board of Directors has declared an interim dividend of ₹4.00 per share, translating to 200% of the face value, with May 30, 2026, set as the record date. This dividend reflects the company’s commitment to creating long-term shareholder value. The company remains in a strong liquidity position, with free cash reserves of ₹1,471 crores and total liquid assets standing at ₹2,726 crores as of March 31, 2026.
Expansion and Market Strategy
Caplin Point continues to strengthen its global footprint, particularly in the US and emerging markets. The company’s US market revenue recorded a 28.7% YoY growth, reaching ₹471 crores. With an enhanced Capex budget of over ₹1,000 crores allocated for investment projects, the company is focused on boosting its production capacities, backward integration, and the development of complex dosage forms, including Pre-Filled Syringes and Blow-Fill-Seal technology. These initiatives, coupled with a debt-free balance sheet, position the company for sustainable long-term growth.
Source: BSE
